Glenmark Pharmaceuticals' US based subsidiary, Glenmark Generic, Inc., has received final approval from US FDA for verapamil extended-release tablets, the generic version of Isoptin SR tablets by Ranbaxy. It received approval on the 240 mg dosage in September 2009 and has continued to build market share on this single strength. The addition of the 120 mg and 180 mg strengths serve to enhance Glenmark's overall market potential.
Verapamil extended-release tablets are indicated in the management of essential hypertension and for the 12 month period ending March 2011 achieved sales of US$ 52 million, according to IMS Health.
The company's current portfolio consists of 72 generic products authorized for distribution in the US market and over 35 ANDAs filed with the US FDA pending approval. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.